Currently undergoing clinical evaluation in ALK and ROS1 fusion-positive NSCLC cancers, PF-06463922, a next-generation ROS1/ALK small-molecule inhibitor, exhibits potent inhibition of various oncogenic ROS1 fusion variants and selective activity against a wide range of kinases (133). Here, ALK is linked to cancer.